依达拉奉联合奥扎格雷钠治疗急性进展性脑梗死对患者ADL与NIHSS评分影响观察

Effect of edaravone combined with ozagrel sodium on ADL and NIHSS score in patients with acute progressive cerebral infarction

目的探讨依达拉奉联合奥扎格雷钠治疗急性进展性脑梗死对患者ADL与NIHSS评分影响。方法选取本院2017年11月至2018年11月收治的130例急性进展性脑梗死患者,随机分为两组,各65例。观察组采用奥扎格雷钠联合依达拉奉治疗,对照组采用奥扎格雷钠。比较两组急性进展性脑梗死患者的ADL评分、NIHSS评分及疗效总有效率。结果观察组诊后ADL评分、NIHSS评分分别为(74.75±11.48)分、(10.78±2.87)分,均优于对照组,差异均有统计学意义(均P<0.05);观察组疗效总有效率98.46%,高于对照组86.15%,差异有统计学意义(P < 0.05)。结论依达拉奉联合奥扎格雷钠治疗方式可有效改善急性进展性脑梗死患者预后,缩短患者神经功能康复时间,临床应用价值较高。

Objective To investigate the effect of edaravone combined with ozagrel sodium on ADL and NIHSS score in patients with acute progressive cerebral infarction. Methods 130 patients with acute progressive cerebral infarction admitted to our hospital from November 2017 to November 2018 were randomly divided into observation group and control group, 65 cases in each group. The observation group was treated with edaravone combined with ozagrel sodium, while the control group was treated with ozagrel sodium. The ADL score, NIHSS score, and total efficacy of the two groups of patients with acute progressive cerebral infarction were compared. Results The ADL score, NIHSS score of the observation group after treatment were (74.75±11.48) and (10.78±2.87), superior to the control group (P<0.05). The total effective rate of the observation group 98.46%, higher than that of the control group (86.15%)(P<0.05). Conclusion Edaravone combined with ozagrel sodium can effectively improve the prognosis of patients with acute progressive cerebral infarction, shorten the recovery time of neurological function, with higher clinical value.